Wellington Management Group LLP Purchases 9,927 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wellington Management Group LLP boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 9.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 114,945 shares of the company’s stock after acquiring an additional 9,927 shares during the quarter. Wellington Management Group LLP’s holdings in Recursion Pharmaceuticals were worth $777,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC lifted its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after buying an additional 1,353 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock valued at $66,000 after buying an additional 6,758 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

RXRX has been the topic of a number of recent analyst reports. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley lowered their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.20.

Recursion Pharmaceuticals Trading Up 27.7 %

Shares of Recursion Pharmaceuticals stock opened at $5.76 on Monday. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The firm has a market capitalization of $2.32 billion, a PE ratio of -3.76 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company’s fifty day moving average price is $6.83 and its two-hundred day moving average price is $6.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.42) EPS. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.